noodls browser compatibility check

The security settings of your browser are blocking the execution of scripts.

To use noodls, javascript support must be enabled. Please change your browser's security settings to enable javascript.

If you have changed your browser's security settings, you can click here.

related announcements

News

ImmuCell Corporation

2025 Form 10-K (proofs 0000811641 118730 ALL DOCS clean pn120)
ImmuCell Corporation

Corporate Presentation (Investor Relations April 2026 Final)
Peakequity Partners Management Co LLC

PeakEquity Partners Successfully Exits G5

Healthcare

Pappas Capital LLC

05/04/2016 | Press release | Archived content

Envisia Therapeutics Announces Positive Three-Month Interim Resul...

News | 05. 04. 2016

Envisia Therapeutics

RESEARCH TRIANGLE PARK, N.C., May 3, 2016 - Envisia Therapeutics, a clinical-stage biotechnology company focused on the development of novel extended-release therapies in ophthalmology, today reported positive results from an interim three-month analysis of an ongoing 12-month safety and efficacy evaluation of the low dosage form of ENV515 XR (travoprost). ENV515, the Company's lead product candidate, is an extended-release formulation of travoprost that could offer sustained reduction in intraocular pressure (IOP) for more than six months after a single dose.

Pappas Capital LLC published this content on May 04, 2016, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on April 22, 2026 at 10:00 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]

Back

View original format